Cannabis industry cashes in: trump-era rescheduling sparks profit surge, Wall Street rush, and research boom—but social justice lags

The Department of Justice's landmark decision to reclassify state-licensed medical marijuana from Schedule I to Schedule III under the Trump administration represents a pivotal shift in federal drug policy, significantly easing regulatory hurdles and catalyzing a surge in cannabis stocks like Tilray, Canopy, and Cronos by up to 13%. While this move stops short of full federal legalization—excluding recreational cannabis—it opens the door for tax relief and regulatory normalization, allowing businesses to deduct expenses previously barred under federal tax codes, thereby improving financial viability across the industry.

Despite these regulatory advancements, the rescheduling does not address the lingering criminal justice ramifications of past marijuana enforcement, such as expungement, resentencing, and reentry challenges that disproportionately affected Black communities. As critics emphasize, this legal recalibration changes market conditions but leaves unresolved the social inequities and personal hardships—lost jobs, deportations, and family separations—that the old Schedule I classification perpetuated, underscoring that cannabis reform remains morally incomplete without these restorative measures.

The DOJ’s proactive scheduling of hearings to consider the rescheduling of marijuana signals an accelerating federal policy evolution, setting the stage for expanded research opportunities and a potential fast-tracking of full recreational legalization timelines. By early 2026, this regulatory momentum under the Trump administration is reshaping the legal landscape, with industry stakeholders and policymakers closely watching how these hearings and subsequent regulatory changes will further dismantle federal barriers and redefine cannabis governance.

The federal rescheduling of cannabis from Schedule I to Schedule III has dramatically improved the financial landscape for cannabis companies by eliminating the punitive Section 280E tax restrictions, which previously imposed effective tax rates as high as 70% to 90%. This shift allows firms like Curaleaf to deduct ordinary business expenses, reducing their tax burden to approximately 21%–28%, thereby transforming negative free cash flow into positive cash flow without requiring revenue growth. As Curaleaf’s CEO highlighted, the removal of a roughly 72% gross margin tax means these companies will now be taxed like any other U.S. corporation, significantly enhancing profitability and cash flow stability.

This newfound profitability and regulatory normalization are catalyzing a wave of industry consolidation and attracting robust institutional investment. Companies with stronger balance sheets, such as Tilray and Canopy Growth, are positioning themselves to capitalize on this environment, with Curaleaf actively engaging in talks with regional and international firms to expand its global footprint. The rescheduling reduces the cost of capital and increases company valuations, setting the stage for a surge in mergers and acquisitions throughout 2026 and 2027 as the market re-rates cannabis stocks to reflect their improved fundamentals.

The market is undergoing a significant re-rating as institutional investors re-enter the cannabis sector, drawn by the elimination of fiscal distortions and enhanced access to traditional financial services. ETFs like AdvisorShares Pure US Cannabis ETF (MSOS) provide direct exposure to operators benefiting most from these changes, signaling a broadening investor base and increased capital inflows. Analysts view this as a tactical investment opportunity with a 12 to 24-month horizon, driven by the sector’s transition from penalization due to regulatory risk to recognition of normalized bottom-line profitability and reduced financial inefficiencies.

Overall, the rescheduling has shifted the cannabis industry’s value proposition from top-line revenue growth to bottom-line profitability, fundamentally altering investor expectations and corporate strategies. As one analysis notes, companies can now create substantial shareholder value simply by normalizing profitability—reducing effective tax rates from around 75% to 25%—without needing to increase sales. This foundational change enables cannabis firms to scale operations more efficiently, access traditional financing, and sustain healthier cash flows, marking a new era of financial viability and market confidence.

The federal rescheduling of cannabis from Schedule I to Schedule III under the Trump administration marks a historic pivot, unlocking the ability for federally funded medical research and clinical trials that were previously barred for over five decades. Boris Jordan highlighted this breakthrough by noting partnerships like the one with the University of Pennsylvania medical center, which will now enable nationwide federally supported studies, signaling a new era of scientific inquiry into cannabis' therapeutic potential.

This policy shift not only broadens research horizons but also accelerates the pursuit of FDA and DEA approvals, which are crucial for legitimizing cannabis as a medical substance and expanding its therapeutic applications. Industry leaders emphasize that such regulatory endorsements will not only validate cannabis scientifically but also unlock commercial benefits, as one CEO remarked, 'I can reward my shareholders with sales and profits' once these approvals are secured.

Scientific validation is gaining momentum, particularly in niche but impactful areas such as pediatric epilepsy, where cannabis' benefits have been described as 'amazing' by industry experts. This growing body of evidence fuels optimism for expanded medical research and underscores the potential for cannabis to become a mainstream therapeutic option backed by rigorous clinical data.

Federal rescheduling of cannabis from Schedule I to Schedule III has catalyzed decisive Treasury actions aimed at integrating the cannabis sector into mainstream financial systems. Treasury Secretary Janet Yellen and Scott Besson have publicly supported enabling major banks to serve cannabis companies and facilitating their listings on U.S. exchanges, signaling a pivotal shift toward normalization. This development is expected to unlock critical financial infrastructure, including widespread access to credit card processing, which industry insiders anticipate will dramatically boost cannabis business volumes.

A key mechanism driving improved financial services access is the pathway for cannabis companies to obtain DEA licenses as federally legal medical entities. This licensing not only legitimizes operations but also positions firms to apply for uplisting on major U.S. stock exchanges such as NASDAQ. As Curaleaf’s CEO noted, the rescheduling is likely to enable uplisting within the next few years, marking a transformative milestone that aligns with broader federal legalization progress and enhances investor confidence.

Industry leaders like Curaleaf’s CEO emphasize that following the rescheduling milestone, the next critical federal focus will be on expanding financial services access for cannabis businesses. This includes improving banking relationships and exchange access, which are essential for scaling operations and facilitating recreational legalization. The CEO’s perspective underscores a strategic sequence where regulatory normalization paves the way for robust financial integration, setting the stage for sustained industry growth.